Loading clinical trials...
Loading clinical trials...
A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-Cell Prolymphocytic Leukemia (R/R T-PLL) or Non-Hodgkin's Lymphoma (NHL).
Conditions
Interventions
APG-115
APG-2575
Locations
1
United States
MD Anderson
Houston, Texas, United States
Start Date
July 12, 2021
Primary Completion Date
May 31, 2026
Completion Date
May 31, 2027
Last Updated
November 4, 2025
NCT00923442
NCT04188678
NCT00179673
NCT00574730
NCT02030834
NCT00739141
Lead Sponsor
Ascentage Pharma Group Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions